The FDA granted Orphan Drug Designation for CMD-003. CMD-003 is a cancer immunotherapy treatment under development by Cell Medica, a London, UK based company for Epstein-Barr Virus (EBV) positive non-Hodgkin lymphomas. Currently, the company is sponsoring phase II clinical trials investigating the safety and efficacy of CMD-003 for the treatment of aggressive extranodal NK/T cell lymphoma (ENKTCL) in patients who have failed previous therapies. CMD-003 is produced by taking patient’s immune cells, activate and expand them ex vivo and reintroduce into patient to recognize and kill malignant cells expressing EBV antigens. Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital have used research prototype of CMD-003 to treat over 250 patients and have achieved promising clinical results across a range of malignancies.